Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/211263
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Blanco Cabra, Núria | - |
dc.contributor.author | Alcàcer Almansa, Júlia | - |
dc.contributor.author | Admella, Joana | - |
dc.contributor.author | Arévalo Jaimes, Betsy Verónica | - |
dc.contributor.author | Torrents Serra, Eduard | - |
dc.date.accessioned | 2024-05-14T08:52:08Z | - |
dc.date.available | 2024-05-14T08:52:08Z | - |
dc.date.issued | 2024-02-25 | - |
dc.identifier.issn | 1939-0041 | - |
dc.identifier.uri | http://hdl.handle.net/2445/211263 | - |
dc.description.abstract | Microbial biofilms are complex three-dimensional structures where sessile microbes are embedded in a polymeric extracellular matrix. Their resistance toward the host immune system as well as to a diverse range of antimicrobial treatments poses a serious health and development threat, being in the top 10 global public health threats declared by the World Health Organization. In an effort to combat biofilm-related microbial infections, several strategies have been developed to independently eliminate biofilms or to complement conventional antibiotic therapies. However, their limitations leave room for other treatment alternatives, where the application of nanotechnology to biofilm eradication has gained significant relevance in recent years. Their small size, penetration efficiency, and the design flexibility that they present makes them a promising alternative for biofilm infection treatment, although they also present set-backs. This review aims to describe the main possibilities and limitations of nanomedicine against biofilms, while covering the main aspects of biofilm formation and study, and the current therapies for biofilm treatment. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine. | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | John Wiley & Sons | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1002/wnan.1944 | - |
dc.relation.ispartof | Wiley Interdisciplinary Reviews-Nanomedicine And Nanobiotechnology, 2024, vol. 16, num. 1 | - |
dc.relation.uri | https://doi.org/10.1002/wnan.1944 | - |
dc.rights | cc by-nc-nd (c) Blanco Cabra, Núria et al, 2024 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Nanomedicina | - |
dc.subject.classification | Polímers | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | Nanomedicine | - |
dc.subject.other | Polymers | - |
dc.subject.other | Therapeutics | - |
dc.title | Nanomedicine against biofilm infections: A roadmap of challenges and limitations | - |
dc.type | info:eu-repo/semantics/other | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2024-05-13T10:57:20Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 6608425 | - |
dc.identifier.pmid | 38403876 | - |
Appears in Collections: | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
2024_WIREsNanNano_Nanomedicine_TorrentsE.pdf | 9.22 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License